Frequency and independent risk factors of sarcopenia in type 2 diabetes

Частота встречаемости и независимые факторы риска саркопении у пациентов с сахарным диабетом 2 типа
Bahar Ozdemir 1, Pinar Karakaya 2, Bulent Yaprak 1, Hakan Kocoglu 1 *
More Detail
1 Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
2 Department of Endocrinology and Metabolic Diseases, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 3, Issue 53, pp. 16-20.
OPEN ACCESS 3053 Views 1788 Downloads
Download Full Text (PDF)


Background: Diabetes is a growing public health problem with the increasing obesity prevalence, and aging world population. Many comorbidities, frailty, and deteriorations in both quality of life and the health status of these patients are associated with a compound outcome of increased body mass index, aging and sarcopenia. Sarcopenia has particular importance, since it is both a cause and an outcome in these patients.
Aim: The aim of this study is to evaluate the sarcopenia frequency, and to determine the independent predictors of sarcopenia in patients with type 2 diabetes.
Methods: Patients between 18 to 65 years of age that followed-up at the Endocrinology Department of Istanbul Bakirkoy Dr. Sadi Konuk Education and Research Hospital with a diagnosis of type 2 diabetes mellitus were evaluated retrospectively.
Results: A total of 86 patients (F/M 60/26) with a mean age of 52.9±12.4 years were included. Fifty-four patients (62.8%) had sarcopenia (70% of females and 46.2% of males; p=0.040), and albumin levels were significantly higher in those patients (p=0.037). Multivariate analyses revealed that females (OR: 3.9; p=0.020), and increased BMI (OR: 1.1 per unit increase; p=0.040), albumin (OR: 2.7 per unit increase; p=0.028) and LDL (OR: 1.02 per unit increase; p=0.016), and decreased Tg (OR: 1.01 per unit decrease; p=0.004) levels were independent determinants of sarcopenia.
Conclusion: Results of this current study confirmed the previous knowledge on the subject, moreover contributes to the available evidence with reporting the increased albumin as a novel risk factor for the sarcopenia.


Ozdemir B, Karakaya P, Yaprak B, Kocoglu H. Frequency and independent risk factors of sarcopenia in type 2 diabetes. Journal of Clinical Medicine of Kazakhstan. 2019;3(53):16-20.


  • Morley J.E., Malmstrom T.K., Rodriguez-Mañas L., Sinclair ve A.J. Frailty, Sarcopenia and Diabetes. Journal of the American Medical Directors Association. 2014; 15(12):853-859.
  • Y. Rolland, S. Czerwinski, G. Abellan Van Kan, J.E. Morley, M. Cesari, G. Onder, J. Woo, R. Baumgartner, F. Pillard, Y. Boirie, W.M. Chumlea, ve B. Vellas. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008. 12(7):433-50.
  • W.J. Lee, L.K. Liu, L.N. Peng, M.H. Lin, L.K. Chen, ve I.R. Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013; 14(7):528 e1-7.
  • T.K. Malmstrom, D.K. Miller, M.M. Herning, ve J.E. Morley. Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle-aged African Americans. J Cachexia Sarcopenia Muscle. 2013; 4(3):179-86.
  • F. Landi, R. Liperoti, A. Russo, S. Giovannini, M. Tosato, E. Capoluongo, R. Bernabei, ve G. Onder. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr. 2012; 31(5):652-8.
  • R.R. Kalyani, M. Corriere, ve L. Ferrucci. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014; 2(10):819-29. 
  • J.I. Barzilay, G.A. Cotsonis, J. Walston, A.V. Schwartz, S. Satterfield, I. Miljkovic, T.B. Harris, ve A.B.C.S. Health, Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged >or=70 years. Diabetes Care. 2009. 32(4):736-8.
  • C.K. Kuo, L.Y. Lin, Y.H. Yu, K.H. Wu, ve H.K. Kuo, Inverse association between insulin resistance and gait speed in nondiabetic older men: results from the U.S. National Health and Nutrition Examination Survey (NHANES) 1999-2002. BMC Geriatr. 2009; 9:49
  • H. Karakelides, Y.W. Asmann, M.L. Bigelow, K.R. Short, K. Dhatariya, J. Coenen-Schimke, J. Kahl, D. Mukhopadhyay, ve K.S. Nair. Effect of insulin deprivation on muscle mitochondrial ATP production and gene transcript levels in type 1 diabetic subjects. Diabetes. 2007; 56(11):2683-9.
  • M. Charlton, ve K.S. Nair. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr. 1998; 128(2):323-327.
  • S.W. Park, B.H. Goodpaster, J.S. Lee, L.H. Kuller, R. Boudreau, N. de Rekeneire, T.B. Harris, S. Kritchevsky, F.A. Tylavsky, M. Nevitt, Y.W. Cho, ve A.B. Newman. Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes. Diabetes Care. 2009; 32(11):1993-1997.
  • Compston J. Type 2 diabetes mellitus and bone. Journal of Internal Medicine. 2018; 283(2):140-153.
  • Turkish Statistical Institute, The Results of Address Based Population Registration System, 2016. 2017; Turkish Statistical Institute: Ankara.
  • Turkish Statistical Institute, Turkey Health Survey, 2016. 2017; Turkish Statistical Institute: Ankara.
  • M. Kose, B. Bora Basara, C. Guler, I. Soytutan Caglar, T. Ozdemir, A. Aygun, S. Uzun, G. Yentur, A. Pekericli, B. Birge Kayis, ve D. Aydogan Kilic. Health Statistics Almanac 2016. 2017; Directorate General for Health Research, Ministry of Health of Turkey: Ankara.
  • A.J. Cruz-Jentoft, J.P. Baeyens, J.M. Bauer, Y. Boirie, T. Cederholm, F. Landi, F.C. Martin, J.P. Michel, Y. Rolland, S.M. Schneider, E. Topinkova, M. Vandewoude, ve M. Zamboni. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010; 39(4):412-423.
  • M. Visser, ve L.A. Schaap. Consequences of sarcopenia. Clin Geriatr Med. 2011; 27(3):387-99.
  • L.J. Anderson, H. Liu, ve J.M. Garcia. Sex Differences in Muscle Wasting. 2017; 1043:153-197.
  • D.H. Sullivan. What do the serum proteins tell us about our elderly patients? J Gerontol A Biol Sci Med Sci. 2001; 56(2): 71-4. https://
  • D.H. Sullivan, P.K. Roberson, L.E. Johnson, P. Mendiratta, M.M. Bopp, ve O. Bishara. Association between inflammation-associated cytokines, serum albumins, and mortality in the elderly. J Am Med Dir Assoc. 2007; 8(7):458-63.
  • T.E. Emerson Jr. Unique features of albumin: a brief review. Crit Care Med. 1989; 17(7):690-4.
  • C.K. Snyder, J.A. Lapidus, P.M. Cawthon, T.-T.L. Dam, L.Y. Sakai, ve L.M. Marshall. Serum Albumin in Relation to Change in Muscle Mass, Muscle Strength, and Muscle Power in Older Men. Journal of the American Geriatrics Society. 2012; 60(9):1663-1672.
  • H. Aleman-Mateo, M.T. Lopez Teros, F.A. Ramirez, ve H. Astiazaran-Garcia. Association between insulin resistance and low relative appendicular skeletal muscle mass: evidence from a cohort study in community-dwelling older men and women participants. J Gerontol A Biol Sci Med Sci. 2014; 69(7):871-7.
  • L.A. Schaap, S.M. Pluijm, D.J. Deeg, ve M. Visser. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006; 119(6):526 e9-17.
  • A.M. Horstman, E.L. Dillon, R.J. Urban, ve M. Sheffield-Moore. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci. 2012; 67(11):1140-52.
  • G. Goldspink, ve S.D. Harridge. Growth factors and muscle ageing. Exp Gerontol. 2004; 39(10):1433-8.
  • M. Gonzalez-Freire, R. de Cabo, S.A. Studenski, ve L. Ferrucci. The Neuromuscular Junction: Aging at the Crossroad between Nerves and Muscle. Front Aging Neurosci. 2014; 6:208.